pamidronic acid Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
calcium metabolism regulator, pharmaceutical aid 2048 40391-99-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pamidronic acid
  • pamidronate disodium
  • pamidronate
  • pamidronate disodium hydrate
An aminobisphosphonate that inhibits BONE RESORPTION and is used for the treatment of osteolytic lesions, bone pain, and severe HYPERCALCEMIA associated with malignancies.
  • Molecular weight: 235.07
  • Formula: C3H11NO7P2
  • CLOGP: -6.17
  • LIPINSKI: 1
  • HAC: 8
  • HDO: 6
  • TPSA: 161.31
  • ALOGS: -1.17
  • ROTB: 4

Drug dosage:

DoseUnitRoute
60 mg P

Approvals:

DateAgencyCompanyOrphan
Oct. 31, 1991 FDA

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteonecrosis 2390.45 51.23 429 1221 12035 4625307
Osteonecrosis of jaw 1799.31 51.23 344 1306 13303 4624039
Bone disorder 829.35 51.23 154 1496 4753 4632589
Tooth extraction 725.82 51.23 134 1516 3978 4633364
Impaired healing 374.99 51.23 88 1562 8391 4628951
Pain in jaw 361.94 51.23 86 1564 8646 4628696
Osteomyelitis 352.45 51.23 79 1571 6129 4631213
Bone debridement 340.94 51.23 49 1601 264 4637078
Femur fracture 337.74 51.23 81 1569 8458 4628884
Sequestrectomy 334.08 51.23 51 1599 439 4636903
Atypical femur fracture 331.46 51.23 58 1592 1231 4636111
Debridement 298.67 51.23 48 1602 592 4636750
Actinomycosis 249.69 51.23 39 1611 394 4636948
Exposed bone in jaw 243.24 51.23 45 1605 1313 4636029
Pain 195.26 51.23 97 1553 92773 4544569
Metastases to bone 185.81 51.23 44 1606 4302 4633040
Bone sequestrum 171.90 51.23 30 1620 621 4636721
Hypocalcaemia 164.01 51.23 45 1605 7916 4629426
Fistula 157.71 51.23 36 1614 2991 4634351
Malignant neoplasm progression 155.93 51.23 59 1591 28977 4608365
Jaw operation 150.95 51.23 25 1625 373 4636969
Hypercalcaemia 135.31 51.23 35 1615 4903 4632439
Jaw disorder 134.87 51.23 29 1621 1827 4635515
Infection 129.88 51.23 55 1595 36087 4601255
Purulent discharge 124.10 51.23 26 1624 1444 4635898
Stress fracture 122.51 51.23 26 1624 1537 4635805
Bone pain 120.28 51.23 40 1610 13446 4623896
Nephrocalcinosis 116.07 51.23 20 1630 382 4636960
Tibia fracture 112.44 51.23 23 1627 1134 4636208
Abscess jaw 110.74 51.23 20 1630 505 4636837
Osteitis 107.68 51.23 22 1628 1078 4636264
Bone lesion 105.70 51.23 22 1628 1182 4636160
Bone lesion excision 101.30 51.23 14 1636 53 4637289
Hyperbaric oxygen therapy 97.81 51.23 14 1636 72 4637270
Pathological fracture 95.02 51.23 22 1628 1938 4635404
Tooth abscess 94.67 51.23 24 1626 3094 4634248
Jaw fracture 91.21 51.23 18 1632 738 4636604
Osteomyelitis chronic 84.86 51.23 14 1636 203 4637139
Osteotomy 82.80 51.23 13 1637 135 4637207
Wound closure 79.93 51.23 12 1638 90 4637252
Osteosclerosis 79.25 51.23 15 1635 492 4636850
Osteolysis 78.67 51.23 16 1634 765 4636577
Wound treatment 77.02 51.23 12 1638 118 4637224
Wound dehiscence 74.22 51.23 17 1633 1426 4635916
Oral surgery 72.17 51.23 14 1636 524 4636818
Toothache 71.30 51.23 20 1630 3786 4633556
Nausea 68.37 51.23 65 1585 177268 4460074
Swelling 67.52 51.23 31 1619 24451 4612891
Pyrexia 67.26 51.23 52 1598 107092 4530250
Product use in unapproved indication 63.48 51.23 30 1620 25243 4612099
Oral disorder 61.85 51.23 16 1634 2229 4635113
Abscess 58.54 51.23 18 1632 4682 4632660
Gingivitis 57.52 51.23 15 1635 2156 4635186
Metastases to liver 55.30 51.23 18 1632 5624 4631718
Blood calcium increased 53.68 51.23 14 1636 2013 4635329
Acute kidney injury 52.62 51.23 38 1612 70393 4566949
Focal segmental glomerulosclerosis 52.26 51.23 11 1639 622 4636720

Pharmacologic Action:

SourceCodeDescription
ATC M05BA03 MUSCULO-SKELETAL SYSTEM
DRUGS FOR TREATMENT OF BONE DISEASES
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
Bisphosphonates
FDA EPC N0000175579 Bisphosphonate
FDA CS M0006519 Diphosphonates
MeSH PA D050071 Bone Density Conservation Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Osteitis deformans indication 2089002 DOID:5408
Humoral hypercalcemia of malignancy indication 47709007
Osteolytic Lesions of Multiple Myeloma indication
Osteolytic Bone Metastases of Breast Cancer indication
Drug-induced osteoporosis off-label use 14651005
Prevention of Glucocorticoid-Induced Osteoporosis off-label use
Bone Metastases off-label use
Hypophosphatemia contraindication 4996001
Hypocalcemia contraindication 5291005
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Periodontitis contraindication 41565005 DOID:824
Hypokalemia contraindication 43339004
Kidney disease contraindication 90708001 DOID:557
Hypomagnesemia contraindication 190855004
Pregnancy, function contraindication 289908002
Aseptic necrosis of bone of jaw contraindication 441809006
Thyroid Surgery contraindication
Invasive Dental Procedure contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.71 acidic
pKa2 4.78 acidic
pKa3 5.76 acidic
pKa4 9.83 acidic
pKa5 13.04 acidic
pKa6 11.49 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Farnesyl pyrophosphate synthase Enzyme INHIBITOR Ki 7.25 CHEMBL CHEMBL
Hypoxanthine-guanine phosphoribosyltransferase Unclassified Ki 4.30 CHEMBL
Farnesyl pyrophosphate synthase Enzyme Ki 6.72 CHEMBL

External reference:

IDSource
D000077268 MESH_DESCRIPTOR_UI
C3714572 UMLSCUI
D00941 KEGG_DRUG
772820008 SNOMEDCT_US
420442001 SNOMEDCT_US
1546406 RXNORM
005066 NDDF
8742T8ZQZA UNII
109552-15-0 SECONDARY_CAS_RN
4674 PUBCHEM_CID
CHEBI:7903 CHEBI
CHEMBL676 ChEMBL_ID
CHEMBL834 ChEMBL_ID
DB00282 DRUGBANK_ID
6305 INN_ID
210 PDB_CHEM_ID
CHEMBL3989401 ChEMBL_ID
7259 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 59923-601 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 mg INTRAVENOUS ANDA 11 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 59923-602 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 6 mg INTRAVENOUS ANDA 11 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 59923-603 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 9 mg INTRAVENOUS ANDA 11 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 61703-324 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 12 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 61703-325 INJECTION, SOLUTION 6 mg INTRAVENOUS ANDA 12 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 61703-326 INJECTION, SOLUTION 9 mg INTRAVENOUS ANDA 12 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-430 INJECTION 3 mg INTRAVENOUS ANDA 12 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-446 INJECTION 9 mg INTRAVENOUS ANDA 12 sections